240 related articles for article (PubMed ID: 9845501)
21. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
Patick AK; Boritzki TJ; Bloom LA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
[TBL] [Abstract][Full Text] [Related]
22. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
23. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
Merrill DP; Moonis M; Chou TC; Hirsch MS
J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
[TBL] [Abstract][Full Text] [Related]
24. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies.
Césaire R; Dos Santos G; Abel S; Bera O; Sobesky G; Cabié A
J Acquir Immune Defic Syndr; 1999 Dec; 22(4):401-5. PubMed ID: 10634203
[TBL] [Abstract][Full Text] [Related]
25. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
26. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
García-Lerma JG; Nidtha S; Heneine W
J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
[TBL] [Abstract][Full Text] [Related]
28. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Palmer S; Alaeus A; Albert J; Cox S
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):157-62. PubMed ID: 9462926
[TBL] [Abstract][Full Text] [Related]
29. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
Middleton T; Smith D; Larder B; Law M; Birch C
HIV Clin Trials; 2001; 2(6):445-52. PubMed ID: 11742431
[TBL] [Abstract][Full Text] [Related]
30. Rational approaches to resistance: nucleoside analogues.
Mayers D
AIDS; 1996 Nov; 10 Suppl 1():S9-13. PubMed ID: 8970670
[TBL] [Abstract][Full Text] [Related]
31. Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
Bélec L; Legoff J; Si-Mohamed A; Andréoletti L; Mbopi-Kéou FX; Kolberg J; Matta M; Detmer J; Piketty C; Kazatchkine MD
J Med Virol; 2002 Sep; 68(1):1-6. PubMed ID: 12210423
[TBL] [Abstract][Full Text] [Related]
32. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
33. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
34. Didanosine: an updated review of its use in HIV infection.
Perry CM; Noble S
Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
[TBL] [Abstract][Full Text] [Related]
35. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
36. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.
Schmit JC; Van Laethem K; Ruiz L; Hermans P; Sprecher S; Sönnerborg A; Leal M; Harrer T; Clotet B; Arendt V; Lissen E; Witvrouw M; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1998 Oct; 12(15):2007-15. PubMed ID: 9814869
[TBL] [Abstract][Full Text] [Related]
37. [Combination of phosphazide and crixivan inhibit replication of HIV-1 strains that are resistant to azidothymidine].
Selimova LM; Kraevskiĭ AA; Galegov GA
Dokl Akad Nauk; 1999 Dec; 369(6):847-9. PubMed ID: 10687056
[No Abstract] [Full Text] [Related]
38. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
Goudsmit J; Weverling GJ; van der Hoek L; de Ronde A; Miedema F; Coutinho RA; Lange JM; Boerlijst MC
AIDS; 2001 Nov; 15(17):2293-301. PubMed ID: 11698703
[TBL] [Abstract][Full Text] [Related]
39. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG
Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485
[TBL] [Abstract][Full Text] [Related]
40. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
